Abstract
Abstract We have previously developed a unique HD-MAC (high-dimensional analysis of molecular alterations in cancer) platform that enables us to define independent tumor biomarkers from a group of clinically-significant genes. Using this platform, 26 genes were identified as independent prognosis biomarkers whose overexpression determine shorter overall survivals in patients with bladder cancer. Through clinical association study (including tumor stage, lymph node invasion, angiogenesis, and metastasis), a gene signature containing 6 biomarkers was established which can be validated by two independent cohorts. Gene knock down effects on cancer cell survival further revealed PPT2 and PRPF19 as potential targets for target-based therapy. Correlation study between genetic dependencies and drug sensitivities across cell lines suggested several potent lead compounds which are likely to function through similar mechanisms of gene effect actions. Our study therefore provides newly defined prognostic biomarkers as well as the associated therapeutic strategies for possible clinical applications in patients with bladder cancer. Citation Format: Jim Jinn-Chyuan Sheu, Chung Chang, Bo-Chen Lin, Tritium Hwang. Novel gene signature for predicting aggressive type of bladder cancer and the associated therapeutic strategies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3161.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
